Is it safe?
Can RXRX take a bad year?
Recursion Pharmaceuticals, Inc. holds $638M more cash than debt, and is burning $81M a quarter, about 2.0 years of cover.
$638M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 0.27
Altman Z-score · distress zone, below 1.8
- Cash runway
- 2.0 years
Cash runway · burning $81M a quarter at the current rate
Details›
- Total debtQ1 2026
- $16M
- Cash and short-term investments
- $654M
- Net cash
- $638M
- EBITDA, trailing twelve months
- −$520M
- Operating profit, trailing twelve months
- −$585M
- Debt / equity
- 0.02×
- Annualised volatilitytwo years of daily moves
- 84%
- Worst drawdown on file
- −93%
- Below its 52-week high
- −49%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.